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Attempts to define the genetic determinants required for efficient growth qf human immunodeficiency virus type 1 (HIV- 
1) in monocyte-macrophages were made by constructing chimeras between two infectious clones of HIV-1 (HXB2 and LW/ 
C), which despite only minor differences in their DNA sequence have striking differences in cell tropism. Although both of 
them replicate fficiently in peripheral blood mononuclear cells, HXB2 replicates extensively in permanent T cell lines but 
poorly in primary monocyte macrophages (T cell line tropic); the reverse is true for LW/C (macrophage tropic). The envelope 
proved to contain the major determinants ofmacrophage tropism. However, tropism determinants appeared to be scattered 
along the envelope. In particular, the V3 loop alone appeared to be neither necessary nor sufficient for growth in macro- 
phages. Both vpr and nef genes appeared to play a less significant role to improve viral replication in macrophages, but 
only in the presence of the proper envelope sequences. HIV-1 macrophage tropism thus appears to result from the 
contribution of several different determinants. 
T-lymphocytes and monocyte-macrophages are major 
targets for human immunodeficiency virus type 1 (HIV-1) 
infection. T-lymphocytes harbor the virus in the periph- 
eral blood compartment and lymph nodes, while mono- 
cyte-macrophages represent a major reservoir in these 
and many other tissues (1-5), such as the central ner- 
vous system (6-11), the infection of which is ultimately 
responsible for several clinical manifestations, including 
acquired immunodeficiency syndrome dementia (8, 12). 
HIV-1 isolates are commonly classified into two major 
groups based on their tropism. One group (monocyte- 
macrophage tropic viruses) is represented by viruses 
which grow efficiently in macrophages and peripheral 
blood lymphocytes (PBL) but are unable to infect perma- 
nent T-cell lines (7). A second group (T-cell line tropic) 
includes viruses which are able to grow in PBL and per- 
manent T-cell lines but fail to grow in monocyte-macro- 
phages. The monocyte-macrophage tropic viruses seem 
to be more prevalent in viral populations in the early 
phases of infection. During progression to disease, how- 
ever, the T-cell tropic variants become more predominant 
(13, 14). 
The env gene of HIV-1 has been defined as a major 
determinant of cell tropism (15-18). An env sequence 
outside the CD4 binding domain and spanning the V3 
loop has been identified as a determinant of tropism for 
macrophages (17- 19) as well as for microglial cells (16), 
and the V3 loop alone has been reporLed as necessary 
and sufficient to confer macrophage tropism (15). Spe- 
cific amino acid substitutions, both within and outside 
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the V3 loop, affecting the overall conformation of gp120, 
were shown to play a role in virus infectivity, host range, 
and syncytium-forming ability (20). The Vl/V2 region was 
also shown as necessary to attain full macrophage tro- 
pism (21). In some strains of HIV-1 even a single amino 
acid substitution in the Vl loop was responsible for a 
change in viral tropism (22). Recently, nef has been 
shown to be a positive factor of viral replication in primary 
PBL and macrophages (23) and required for high titer 
production and pathogenesis following in vivo infection 
of macaques with simian immunodeficiency virus (SIV) 
(24). It has been suggested that Vpr, a virion-associated 
regulatory protein (25), plays a role in macrophage tro- 
pism for HIV-1 and HIV-2 (26, 27). 
We repot[ here the results of studies with chimeric 
viruses containing combinations of fragments of enve- 
lope gene from macrophage tropic and T-cell line tropic 
H IV isolates, and we analyze the contributions of different 
regions of the viral sequence for their ability to grow in 
macrophages. 
The two infectious molecular clones (pHXB2 and pLW/ 
C) were both derived from HIV-I(HTLV-IIIB) and were 
consequently very similar in nucleotide identity (2% differ- 
ence). In spite of their close similarities, viruses derived 
from these clones had reciprocal cellular host ranges. 
HXB2 grows extremely well in permanent T-cell lines and 
peripheral blood mononuclear cells (PBMC), but grows 
poorly and inconsistently in primary monocyte-macro- 
phages. In contrast, LW/C, constructed from the clone 
LW 12.3 derived from the isolate of a laboratory worker 
accidentally infected with HIV-I(HTLV-IIIB), replicates ex- 
tremely well on monocyte-macrophages and PBMC, but 
not in T-cell lines. 
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RG. 1. (A) Genetic structure of molecular clones HXB2 and LW/C and positions of the restriction sites used for chimeric constructs. LW/C clone 
was prepared from clone LW 12.3 (33) by repairing the vff and vpr genes using the appropriate region from the HIV-I (FITLV-IIIB) clone pHXB2gpt 
(34). (B) HXB2 (Sat-Xba LW) was constructed by replacing the SalI-Xbal fragment of HXB2 with the corresponding fragment from LW/C. HXB2 
(Sa/-Esp LW) was constructed by replacing the SalI-Espl fragment of HXB2 with the corresponding fragment from LW/C. LW (SaI-Esp HXB2) was 
constructed by replacing the Sa/I-Espl fragment of LW/C with the corresponding fragment from HXB2. FIXB2 (Esp-Xba LW) was constructed by 
replacing the Espl-Xbal fragment of HXB2 with the corresponding fragment from LW/C. LW (Esp-Xba I~XB2) was constructed by replacing the 
Espf-Xbal fragment of LW/C with the corresponding fragment from HXB2. HXB2 (vpr +) was constructed by replacing the EcoRI-Sall fragment of 
HXB2 by the corresponding fragment from LW/C. LW (vpr-tr) was constructed by replacing the EcoRI-Sa/I fragment of LW/C with the corresponding 
fragment from HXB2. HXB2 (SaI-Pvu LW) was constructed by replacing the SatI-Pvull fragment of HXB2 with the corresponding fragment from 
LW/C. HXB2 (Pvu-Esp LW) was constructed by replacing the EspI-Pvutl fragment of HXB2 with the corresponding fragment from LW/C. The 
construction of the V3 loop cassette is as described in Di Marzo Veronese et al. (35). The IlIB V3 loop sequence, which differs from LW/C by a 
single amino acid substitution, GPGRA/TF, was introduced into LW/C by polymerase chain reaction (PCR)-mediated site-directed mutagenesis. A 
0.5-kbp PvulI-Bgtll fragment of LW/C, containing the V3 loop coding region, was amplified in two separate PCRs to generate partially overlapping 
fragments, each containing the desired mutation. The primers used were: A, 5'-CCGATTCAqq-AATGCAGCTGAACCA-3'; B, 5'-lq-CCTATFGTAACAA- 
AGGCGCGCCCTGGTCCTCTCTG-3'; C, 5'-CAGAGAGGACCAGGGCGCGCOFFTGTTACAATAGGAA-3'; D, 5'-CACFI-CTCCAATiGTCCCTCATATC-3'. 
Primers A and B were used together, as were primers C and O. Primers B and C introduced a Ascl site (underlined) in addition to the A to T amino 
acid substitution. The two fragments were purified, denatured, annealed, and reamplified to produce a mutated PvulI-Bglll 0.5-kbp fragment, which 
was substituted for the wild-type LW/O PvulI-Bglll fragment in an LW/C subclone of a 1.3-kbp PvulI-BamHt env subclone in pGEM4 (Promega, 
Madison, Wt). The recombinant PvulI-BamHI fragment was substituted for the homologous wild-type fragment in a Sa/I-Espl 2.9-kbp subclone of 
LW/C in pGEMEX2 (Promega). Finally, the recombinant SalI-Espl fragment was substituted for the homologous fragment in the LW/C complete 
clone in the SP65gpt vector, which was used in transfections as a source of infectious virus. The presence of the mutation was verified by Ascl 
digestion and by sequencing the amplified mutated region. (C) V3 loop sequences of HXB2, LW/C, MN ST.f, and Ba-L are illustrated. Amino acid 
residues different from those of HXB2 are indicated by asterisks. Gaps in the sequences are indicated by spaces. The sequence of the V3 loop 
was from Ratner et aL (36), that of MN was from Gurgo et aL (37), and those of LW/O and Ba-L were determined here. 
As shown in Fig, 1A, three of the open reading frames 
(vpr, vpu, and nef) are complete in LW/C but not in HXB2. 
The remainder of the proteins from the two viruses, how- 
ever, are very similar in their inferred amino acid se- 
quences. These infectious clones were accordingly used 
to construct a variety of chimeric viruses. 
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FIG. 2. Growth of HXB2-LW/C chimeric viruses in macrophages. (A) Growth of HXB2, LW/C, HXB2(SaI-Xba LW), HXB2(SaI-Esp LW), and LW(Sal- 
Esp HXB2), (B) Growth of HXB2, LW/C, HXB2(SaI-Pvu LW), and HXB2(Pvu-Esp LW). (C) Growth of HXB2 with V3 loop from LW/C. (D) Shown is the 
kinetic of growth in macrophages of chimeric viruses with substituted vpr gene (LW with vpr from HXB2 and vice versa). LW(Esp-Xba HXB2) 
contains nef from HXB2. Virus preparation, Transfection of HeLa-Tat cells (38) with plasmids containing chimeric constructs was performed by 
using the calcium precipitation method (39). Cell culture supernatant was collected after 48 hr and then used as the viral source for the infection 
of macrophages. Cell preparation= Blood from normal donors was used for the Ficoll gradient centrifugation preparation of PBMC. Monocytes were 
selected by adherence on the plastic pretreated with human serum. For 24-well plates, 5 x 106 PBMC were plated per well. For 25-cm 2 flask, 5 X 
107 PBMC were plated. Macrophages were grown in the presence of 10 U/ml of granulocyte-macrophage colony stimulating factor in RPMI 1640 
containing 10% fetal calf serum (Hyclone, Logan, UT) 14 days before infection. Infection and virus detection: Macrophages were infected by using 
an amount of virus corresponding to 100,000 cpm of reverses transcriptase (RT) activity per flask or 10,000 cpm per well. Production of HIV-1 p24 
was measured by antigen capture assay. RT activity was measured by standard protocols. Results shown are representatives of at least three 
experiments on macrophages derived from different blood donors. 
The ability of different viral chimerae to grow in macro- 
phages indicated the importance for macrophage tro- 
pism of determinants in the LW/C envgene (Figs. 2A and 
2B). HXB2(Sal-Xba LW), which contained the right half 
(including vpu, env, nef, tat, rev, and 3' long terminal 
repeat) of the LW/C provirus, replicated in macrophages 
nearly as efficiently as LW/C (Fig. 2A). Another pair of 
reciprocal chimeras contained either the vpu, rev, tat, 
and env of LW within the HXB2 genetic backbone 
(HXB2[SaI-Esp LW]) or vice versa (LW[SaI-Esp HXB2]). 
Substitution of the SalI-Espl fragment of HXB2 into LW/ 
C resulted in a virus with a low replication rate in macro- 
phages, In contrast, the SalI-Espl fragment of LW/C con- 
ferred on HXB2 the ability to replicate in macrophages 
at 55-60% the rate of LW/C (Fig. 2A). 
The env gene of the IIIB family of HIV-1 contains a 
Pvull site just 5' of the coding region for hypervariable 
region 3 (V3), a loop bounded by cysteine residues which 
constitutes a target for neutralizing antibodies and which 
has been reported to be critical for cellular host ranges. 
Substitution of the SalI-Pvull or the PvulI-Espl fragment 
from LW/C into HXB2 did not significantly increase the 
ability of the resultant viruses to grow in macrophages 
(Fig. 2B). These data suggested that determinants distrib- 
uted over different parts of the env gene of LW/C contrib- 
ute in concert to its ability to grow in macrophages, but 
are not active individually. They also suggested that the 
V3 of LW/C did not play a primary role in determining its 
ability to grow on macrophages. 
To further ascertain the contribution of the V3 region 
to the determination of the ability of LW/O but not NXB2 
to grow on macrophages, a series of chimeric viruses 
were constructed in which only the V3 loops were 
changed. HXB2 containing the V3 loop of LW/C grew as 
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FIG. 3. Contribution of env, vpr, and neffor growth in macrophages. 
Calculation of the average growth in macrophages (compared to the 
LW/C clone) of clones which had LW/C genes in the backbone of 
HXB2. (X axis legend) HXB2, average for HXB2 and HXB2(LWV3); +vpr, 
average for HXB2vpr+; +vpr 4- nef, average for LW(SaI-Esp HXB2); 
+env, average for HXB2(SaI-Esp LW); +env + vpr, average for 
LW(Esp-Xba HXB2); +env + nef, average for LW(SaI-Xba HXB2); and 
growth of LW/C is shown as 100%. 
poorly in macrophages as did HXB2 (Fig. 2C). A chimera 
of LW/O which contained the V3 loop of HXB2 replicated 
as well in macrophages as did the parental LW/C (not 
shown). 
Ohimeras were also constructed which contained the 
V3 loops of two other macrophage tropic viruses, HIV- 
I(Ba-L) and (MN ST.1). Neither of the HXB2 chimeric 
viruses containing V3 loops from MN ST.1 or Ba-L repli- 
cated in macrophages more efficiently than HXB2 itself 
(not shown). 
LW(Esp-Xba HXB2), which has the incomplete nef of 
HXB2, showed a decrease in the ability to replicate in 
macrophages when compared with LW/C (Fig. 2D). Fur- 
thermore, HXB2(SalI-Xbal LW), containing both the env 
and nef genes of LW, grew better in macrophages than 
did HXB2(SalI-Espl LW), which has the truncated nef 
gene of HXB2 (Fig. 2A). However, LW(SaI-Esp HXB2), 
containing the nefgene of LW but the envgene of HXB2 
could not grow in macrophages (Fig. 2B). These data 
suggested that nef was able to positively contribute in 
growth in macrophages, but only in the context of viruses 
with an effective (i.e., LW/C) envelope. 
Figure 3 illustrates data obtained by calculating the 
average growth in macrophages for at least three experi- 
ments of the clones which had either vpr, nef, or env 
or the combination of these genes from LW/C, in the 
backbone of HXB2. Such analysis confirmed that env is 
the major determinant for macrophage tropism. Further- 
more, both vpr and nef contributed to better growth in 
macrophages, but to a lesser extent, and only when the 
macrophage-tropic envelope was also present. Although 
the difference between averages of HXB2(SaI-Esp LW) 
(+env) and LW(SaI-Xba HXB2) (+env + nef) was not 
statistically significant (only 27%), and the difference be- 
tween env+ and env 4- vpr was 17%, one can claim the 
existence of tendency for positive contribution of vpr and 
nefgenes for growth of HIV-1 in macrophages. 
The appropriate env gene of HIV-1 has been reported 
to be necessary and sufficient to confer tropism for mac- 
rophages upon HIV-1 (11, 15-17). Our data are at least 
partially consistent with this idea, since the macrophage 
tropism of our constructs correlates with the presence 
of the env gene of the macrophage tropic clone LW/C 
(see Fig. 2A). However, our data showed that the determi- 
nants of the envelope gene necessary for the macro- 
phage tropism of LW/C did not map to a single region, 
since two subclones containing only part of the LW/C 
env sequence (the first one spanning the region of Vl 
and V2 loops and the second one spanning the region 
of V3 loop, as well as CD4 binding site and gp41) failed 
to grow as efficiently in macrophages as LW/C (see Fig. 
2B). This is in agreement with recent observations with 
SlY showing that the determinants for macrophage tro- 
pism are scattered along the env gene (28) and study of 
the role of V1/V2 domains in cell tropism (21). 
A restricted region of the envelope, the V3 loop, which 
is known to be the principal neutralizing determinant of 
HIV-1 (29-31), has been reported to be sufficient for 
macrophage tropism (15). Our data do not support this 
conclusion, since all our constructs containing the V3 
loop from viruses able to grow well in monocyte-macro- 
phages within the envelope from a nonmacrophage 
tropic virus, HXB2, show little or no growth in macro- 
phages. Moreover, LW/C containing the V3 loop of the 
HXB2 clone was still able to grow in macrophages at 
levels comparable with the LW/C wild-type, indicating 
that V3 loop was not only insufficient but also unneces- 
sary to determine the macrophage tropism of LW/C. 
These results, taken as a whole, suggest that the proper- 
ties of the envelope to confer the ability of the virus to 
infect and be expressed in macrophages are determined 
by the overall tertiary structure of the envelope protein 
rather than by particular limited stretches of contiguous 
amino acid residues. In some viral strains the V3 loop 
could be the primary determinant (15). In others, like 
those analyzed here, the determinants necessary to con- 
fer macrophage tropism upon the nonmacrophage tropic 
partner are more extensively distributed and a larger 
sequence must be switched for efficient growth. 
In our experiments, repair of vpr in HXB2 did not confer 
the ability to replicate in macrophages unless in the con- 
text of the proper env. Since it has been suggested (32) 
that vpr is necessary for efficient replication of the virus 
in CD4 + cell cultures, vpr may have a generic effect on 
the efficacy of HIV-1 replication rather than its specific 
role in macrophage tropism. Similar consideration could 
apply to the role of nef (23). Although the role of vpu has 
not been addressed in these experiments, indications 
that vpu does not play a specific role on macrophage 
tropism have been obtained by using another clone, MN- 
ST1 (33) (not shown). 
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In conclusion, we suggest that macrophage tropism 
of HIV-1 does not seem to have a single discrete determi- 
nant. The V3 loop alone appears to be neither necessary 
nor sufficient to confer macrophage tropism on HXB2 or 
reduce it with LW/C. Reports from others (15), which 
indicate that the V3 loop is both necessary and sufficient 
to confer macrophage tropism, could be due to the differ- 
ent genetic context (HXB3 versus HXB2) into which their 
chimeric loops have been introduced. The assignment 
of tropism determinants thus may depend on the particu- 
lar pair of viruses being compared. Our results indicate 
that determinants from macrophage-tropic viruses not 
contained in V3 are required for the ability to grow in 
macrophages. However, while the proper tertiary struc- 
ture of envelope appears to be critical for growth in mac- 
rophages, regions outside the envelope (such as nefcon- 
taining region downstream from the env and vpr) could 
also be important, but only when the proper envelope 
gene is present. 
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